Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program

Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program

Abstract Background Patients with type 2 diabetes (T2D) are predisposed to derangements in serum Magnesium (Mg), which may have implications for cardiometabolic events and outcomes. In clinical trials, participants with T2D randomized to sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have shown...

Full description

Bibliographic Details
Main Authors: Katherine M. Wang, JingWei Li, Vivek Bhalla, Meg J. Jardine, Bruce Neal, Dick deZeeuw, Greg Fulcher, Vlado Perkovic, Kenneth W. Mahaffey, Tara I. Chang
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:Endocrinology, Diabetes & Metabolism
Subjects:
canagliflozin
cardiovascular outcomes
magnesium
type 2 diabetes
Online Access:https://doi.org/10.1002/edm2.247

Internet

https://doi.org/10.1002/edm2.247

Similar Items